Display options
Cite
Lopate G, Pestronk A. Inflammatory demyelinating neuropathies. Curr Treat Options Neurol. 2011;13(2):131-42doi: 10.1007/s11940-011-0114-0.
Lopate, G., & Pestronk, A. (2011). Inflammatory demyelinating neuropathies. Current treatment options in neurology, 13(2), 131-42. https://doi.org/10.1007/s11940-011-0114-0
Lopate, Glenn, and Pestronk, Alan. "Inflammatory demyelinating neuropathies." Current treatment options in neurology vol. 13,2 (2011): 131-42. doi: https://doi.org/10.1007/s11940-011-0114-0
Lopate G, Pestronk A. Inflammatory demyelinating neuropathies. Curr Treat Options Neurol. 2011 Apr;13(2):131-42. doi: 10.1007/s11940-011-0114-0. PMID: 21243541.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Neurol. 2011 Apr;13(2):131-42. doi: 10.1007/s11940-011-0114-0.

Inflammatory demyelinating neuropathies.

Current treatment options in neurology

Glenn Lopate, Alan Pestronk

Affiliations

  1. Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8111, St. Louis, MO, 63110, USA, [email protected].

PMID: 21243541 DOI: 10.1007/s11940-011-0114-0

Abstract

OPINION STATEMENT: The primary goal of therapy in patients with the Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is improved strength and functional ability. Improvement in pain, sensory loss, gait disorder, and autonomic instability are other goals of therapy. Patients with very mild symptoms that do not interfere with activities of daily living can be observed for deterioration without treatment. For GBS, standard care includes plasma exchange (PE) or human immune globulin (HIG), both of which have similar efficacy. Supportive care in the intensive care unit may be needed for those patients with severe bulbar or respiratory weakness. We treat most patients with PE, usually performing an exchange every other day for a total of five exchanges. We use HIG in children, if there are antiglycolipid antibodies (eg, anti-GM1 or anti-GQ1b) or if there is a contraindication to PE, such as hemodynamic instability; severe renal, hepatic, or cardiac disease; or poor venous access. For CIDP, there are no guidelines concerning the initial choice of therapy. Corticosteroids, HIG, and PE have all been shown to be effective in prospective, randomized controlled trials, and comparison trials have shown equal efficacy among these three immunomodulating therapies. The choice of therapy depends on several factors including disease severity, concomitant illnesses, side-effect profile, potential drug interactions, venous access, age-related risks, and cost of treatment. In patients with moderate to severe symptoms, treatment with corticosteroids or HIG should be used. We usually use high-dose, intermittent methylprednisolone as the initial drug of choice. We believe intermittent corticosteroids are better than HIG because of their good safety profile, low cost, ease of administration (can be given intravenously or by mouth), and proven efficacy. If there is a major contraindication to corticosteroids, then HIG is offered. PE is less well tolerated and is primarily used as a third choice and only for a few weeks to months to induce initial improvement. Once symptoms are improving, the dose of corticosteroids or HIG should be tapered with the goal of eventual discontinuation depending on patient response. Patients who do not respond to initial therapy, experience adverse effects from the initial immunomodulating agent, or require chronic treatment can be treated with another first-line agent or one of several second-line agents.

References

  1. J Neurol Neurosurg Psychiatry. 2010 Jul;81(7):726-30 - PubMed
  2. J Clin Apher. 1999;14(3):107-13 - PubMed
  3. Neurology. 1996 Jul;47(1):98-102 - PubMed
  4. J Neurol. 1996 Mar;243(3):280-5 - PubMed
  5. Brain. 1996 Aug;119 ( Pt 4):1067-77 - PubMed
  6. N Engl J Med. 1991 Nov 21;325(21):1482-6 - PubMed
  7. J Peripher Nerv Syst. 2005 Mar;10(1):11-6 - PubMed
  8. Pediatr Neurol. 2001 Mar;24(3):177-82 - PubMed
  9. Lancet Neurol. 2010 Mar;9(3):245-53 - PubMed
  10. Arch Neurol. 2008 Nov;65(11):1460-4 - PubMed
  11. Neurology. 2007 Oct 30;69(18):1802-3 - PubMed
  12. Neurology. 2001 Feb 27;56(4):445-9 - PubMed
  13. J Neurol Neurosurg Psychiatry. 2010 Jun;81(6):634-6 - PubMed
  14. Ann Neurol. 1997 Mar;41(3):298-306 - PubMed
  15. Neurology. 1985 Aug;35(8):1096-104 - PubMed
  16. Ann Neurol. 2001 Aug;50(2):195-201 - PubMed
  17. Brain. 1995 Apr;118 ( Pt 2):359-68 - PubMed
  18. Ann Neurol. 1994 Dec;36(6):838-45 - PubMed
  19. Neurology. 1998 Dec;51(6):1735-8 - PubMed
  20. Ann Neurol. 1981;9 Suppl:134-45 - PubMed
  21. J Neurol Neurosurg Psychiatry. 1996 Feb;60(2):185-7 - PubMed
  22. Lancet. 1997 Jan 25;349(9047):225-30 - PubMed
  23. Lancet. 1984 Dec 8;2(8415):1296-9 - PubMed
  24. Scand J Infect Dis. 1995;27(3):241-3 - PubMed
  25. Lancet Neurol. 2008 Feb;7(2):136-44 - PubMed
  26. N Engl J Med. 1992 Apr 23;326(17):1123-9 - PubMed
  27. Neurology. 2004 Aug 24;63(4):715-7 - PubMed
  28. Neurology. 1997 Feb;48(2):321-8 - PubMed
  29. J Peripher Nerv Syst. 2009 Jun;14(2):118-24 - PubMed
  30. N Engl J Med. 1986 Feb 20;314(8):461-5 - PubMed
  31. Eur J Neurol. 2007 Aug;14(8):e1-2 - PubMed
  32. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):388-90 - PubMed
  33. Muscle Nerve. 1998 Apr;21(4):454-60 - PubMed
  34. Lancet. 1984 Apr 21;1(8382):877-9 - PubMed
  35. Muscle Nerve. 2001 Jan;24(1):54-8 - PubMed
  36. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):36-9 - PubMed
  37. Neurology. 1996 Jan;46(1):100-3 - PubMed
  38. Muscle Nerve. 2008 Mar;37(3):406-9 - PubMed
  39. Pediatrics. 2005 Jul;116(1):8-14 - PubMed
  40. Ann Neurol. 1987 Dec;22(6):753-61 - PubMed
  41. J Neurol. 2010 Jun;257(6):913-9 - PubMed
  42. J Neurol Sci. 1998 Jan 21;154(1):66-71 - PubMed
  43. Arch Neurol. 2005 Feb;62(2):249-54 - PubMed
  44. Neuromuscul Disord. 2000 Aug;10(6):398-406 - PubMed
  45. Brain. 1996 Aug;119 ( Pt 4):1055-66 - PubMed
  46. Ann Neurol. 1982 Feb;11(2):136-41 - PubMed
  47. Neurology. 1985 Aug;35(8):1173-6 - PubMed
  48. Ann Neurol. 2000 Mar;47(3):314-21 - PubMed
  49. Pharmacol Ther. 2004 Jun;102(3):177-93 - PubMed

Publication Types